| Patents for A61K 39 - Medicinal preparations containing antigens or antibodies (182,248) |
|---|
| 01/26/2006 | WO2006007848A2 Immune modulating compounds from fungi |
| 01/26/2006 | WO2005116064A3 Altered fibronectin-binding protein of staphylococcus aureus |
| 01/26/2006 | WO2005115456A9 METHODS OF MODULATING THE REPRODUCTIVE ENDOCRINE SYSTEM BY MODULATION OF TNFαACTIVITY |
| 01/26/2006 | WO2005112996B1 1,4 o-linked saccharose derivatives for stabilizing antibodies or antibody derivatives |
| 01/26/2006 | WO2005077408A3 Compositions of pamps and listeria monocytogenes and methods of use |
| 01/26/2006 | WO2005076843A3 Methods and compositions for treating tumors and metastatic disease |
| 01/26/2006 | WO2005060999A3 Detection of cd20 in therapy of autoimmune diseases |
| 01/26/2006 | WO2005055979A3 Ph triggerable polymeric particles or films containing a poly (beta-amino ester) |
| 01/26/2006 | WO2005046605A3 Compositions and methods of treating neurological diseases |
| 01/26/2006 | WO2005037233A3 Listeria-based epha2 vaccines |
| 01/26/2006 | WO2005037205A3 Haloacetamide and azide substituted compounds and methods of use thereof |
| 01/26/2006 | WO2005035584A8 Fully human antibodies against human 4-1bb (cd137) |
| 01/26/2006 | WO2005028618A3 Immunogenic compositions for streptococcus agalactiae |
| 01/26/2006 | WO2005014037A3 Polysaccharide-protein conjugate vaccines |
| 01/26/2006 | WO2005012538A3 Accelerated vaccination |
| 01/26/2006 | WO2005005462A3 Blys antagonists and uses thereof |
| 01/26/2006 | WO2004045532A3 Methods for preventing and treating cancer metastasis and bone loss associated with cancer metastasis |
| 01/26/2006 | WO2004045507A3 Anti-angiogenic uses of il-6 antagonists |
| 01/26/2006 | WO2004018630A3 Recombinant double-stranded rna phages and uses thereof |
| 01/26/2006 | US20060021071 Cell in which genome is modified |
| 01/26/2006 | US20060020128 Therapy-enhancing glucan |
| 01/26/2006 | US20060020119 Monoclonal antibodies to gastrin hormone |
| 01/26/2006 | US20060020113 Human Six Transmembrane Epithelial Antigen of the Prostate (STEAP) protein; folds in a "serpentine" manner into three extracellular and two intracellular loops; used for diagnosis and treatment of prostate cancer |
| 01/26/2006 | US20060020024 TNP-470 species, polymer conjugates and use thereof |
| 01/26/2006 | US20060019924 used in neuroblastoma therapy and diagnosis |
| 01/26/2006 | US20060019921 Nucleic acid adjuvants |
| 01/26/2006 | US20060019909 Modulation of immunostimulatory properties of oligonucleotide-based compounds by optimal presentation of 5' ends |
| 01/26/2006 | US20060019887 Compositions and methods for the prevention or treatment of cancer and bone loss associated with cancer |
| 01/26/2006 | US20060019369 for the production of reconstituted HCMV virus retaining phenotypic characteristics of a clinical virus isolate including the ability to grow on endothelial cells and to induce microfusion |
| 01/26/2006 | US20060019350 Recombinant negative strand RNA virus expression system and vacccines |
| 01/26/2006 | US20060019344 C-erbB-2 external domain: gp75 |
| 01/26/2006 | US20060019318 Conformational and topological protein regulation |
| 01/26/2006 | US20060019310 Cell regulatory genes, encoded products, and uses related thereto |
| 01/26/2006 | US20060019240 Posh nucleic acids, polypeptides and related methods |
| 01/26/2006 | US20060019239 enhancing the immunogenicity of a vaccine against Bacillus anthracis by administering an oligodeoxynucleotide with a vaccine against Bacillus anthracis; Anthrax Vaccine Adsorbed (AVA) vaccine |
| 01/26/2006 | US20060018971 Nucleic acid microspheres, production and delivery thereof |
| 01/26/2006 | US20060018932 Recombinant protein containing a C-terminal fragment of Plasmodium MSP-1 |
| 01/26/2006 | US20060018931 Therapeutic composition with a botulinum neurotoxin |
| 01/26/2006 | US20060018930 Compositions comprising viruses and methods for concentrating virus preparations |
| 01/26/2006 | US20060018929 Protein kinase deficient, immunologically active CMVpp65 mutants |
| 01/26/2006 | US20060018928 Virus-like particle containing a dengue virus recombinant replicon |
| 01/26/2006 | US20060018927 Major nucleocapsid protein/phosphoprotein, large polymerase protein, a M2 (ORF1) RNA polymerase elongation factor, and RSV genome/antigenome of human strains; point mutations; glycoproteins; immunogens |
| 01/26/2006 | US20060018926 Noscapine derivatives as adjuvant compositions and methods of use thereof |
| 01/26/2006 | US20060018925 Compositions and methods for modulating RSV infection and immunity |
| 01/26/2006 | US20060018924 Recombinantly produced, enzymatically active, includes two amino acid motifs |
| 01/26/2006 | US20060018923 A nucleotide sequence along with the deduced amino acid sequences of the complete genomic sequence of a novel human coronavirus (CoV-HKU1) of the order Nidovirales; single-stranded RNA virus of positive polarity; immunogenic/vaccine preparations using recombinant and chimeric forms; vectors; cells |
| 01/26/2006 | US20060018921 Histone deacetylase inhibitors and cognitive applications |
| 01/26/2006 | US20060018920 Lawsonia derived gene and related OmpH polypeptides, peptides and proteins and their uses |
| 01/26/2006 | US20060018919 Peptide mimotopes of lipooligosaccharide from nontypeable Haemophilus influenzae as vaccines |
| 01/26/2006 | US20060018918 Production of stabilized conformational isomers of disease associated proteins |
| 01/26/2006 | US20060018917 Nucleic acid and corresponding protein named 158P1D7 useful in the treatment and detection of bladder and other cancers |
| 01/26/2006 | US20060018916 Compositions and methods for eliciting an immune response to gram-negative bacterial infections |
| 01/26/2006 | US20060018915 Heteroclitic analogs and related methods |
| 01/26/2006 | US20060018914 Novel antibody conjugates reactive with human carcinomas |
| 01/26/2006 | US20060018913 Complex of monoclonal antibodies with label; antitumor agents; anticancer agents |
| 01/26/2006 | US20060018912 Snares for pathogenic or infectious agents and uses related thereto |
| 01/26/2006 | US20060018911 Design of therapeutics and therapeutics |
| 01/26/2006 | US20060018910 Administering anti-insulin-like growth factor I receptor (IGF-1R) antibodies to treat advanced non-small cell lung cancer |
| 01/26/2006 | US20060018909 Angiopoietin-2 specific binding agents |
| 01/26/2006 | US20060018908 Soluble composition comprising an anti-EGF receptor antibody linked via a carrier moiety to a substituted 3-indoxyl phosphate which is linked to phosphoenolpyruvate. |
| 01/26/2006 | US20060018907 Treating psoriatic arthritis using an antibody that competitively inhibits binding of monoclonal antibody A2 or chimeric monoclonal antibody cA2 to TNF-alpha, and binds to a neutralizing epitope of TNF-alpha with a specified association constant (Ka) determined by Scatchard analysis |
| 01/26/2006 | US20060018906 monoclonal antibody for treating cancer, neovascularization, vascular and arthritic diseases; immunoassay; immunotherapy; inhibition or antagonism of TNF decreases expression of Vascular Endothelial Growth Factor (VEGF) or Vascular Permeability Factor (VPF); decrease angiogenesis |
| 01/26/2006 | US20060018905 Methods for treating systemic lupus erythematosus using anti-TNF antibodies and fragments thereof |
| 01/26/2006 | US20060018904 Combination therapies utilizing benzamide inhibitors of the P2X7 receptor |
| 01/26/2006 | US20060018903 Tumor necrosis factors (TNF); site-directed mutagenesis, genetic deletions; monoclonal antibodies with decreased immunogenicity and lymphocyte epitopes; major histocompatibility complex binding ligands; for treatment of rheumatoid arthritis and Crohn's disease |
| 01/26/2006 | US20060018902 Antibodies to erythropoietin receptor and uses thereof |
| 01/26/2006 | US20060018901 Use of antibodies in a very low dose for the vaccination against cancer |
| 01/26/2006 | US20060018900 Self antigen vaccines for treating B-cell lymphomas and other cancers |
| 01/26/2006 | US20060018899 HER2 antibody composition |
| 01/26/2006 | US20060018898 Antibody variants |
| 01/26/2006 | US20060018897 Bispecific antibodies |
| 01/26/2006 | US20060018896 Methods for treating conditions associated with lectin-dependent complement activation |
| 01/26/2006 | US20060018895 Murine monoclonal anti-idiotype antibody 11D10 and methods of use thereof |
| 01/26/2006 | US20060018893 Method for determining modulation of P110delta activity |
| 01/26/2006 | US20060018888 Suicidal mutant leishmania vaccine |
| 01/26/2006 | US20060018881 Coordinate in vivo gene expression |
| 01/26/2006 | US20060018880 Methods and compositions for delivery of an enhanced response to antigenic substrates |
| 01/26/2006 | US20060018878 Dual antigen specific T cells with trafficking ability |
| 01/26/2006 | US20060018877 Intradermal delivery of vacccines and therapeutic agents |
| 01/26/2006 | US20060018876 Treatment of diseases caused by viral infection |
| 01/26/2006 | US20060018874 Fatty acid formulations for oral delivery of proteins and peptides, and uses thereof |
| 01/26/2006 | US20060018873 inducing in a patient, at least one activity of IL-2 selected from increasing humoral immune responses and increasing cellular immune responses, by administering to said patient a therapeutically effective amount of a peptide sufficient to induce the activity |
| 01/26/2006 | US20060018844 Botulinum toxin dental therapy for angular cheilosis |
| 01/26/2006 | US20060018836 Method for treating human tumor cells with a newcastle disease virus strain having a p53 independent oncolytic effect |
| 01/26/2006 | US20060018826 Biologic modulations with nanoparticles |
| 01/26/2006 | CA2612303A1 Anti-glycated cd59 antibodies and uses thereof |
| 01/26/2006 | CA2574302A1 Stable compositions containing outer membrane vesicles, methods of manufacturing |
| 01/26/2006 | CA2574093A1 Prevention of allergy in children |
| 01/26/2006 | CA2574062A1 Anti-rhesus d recombinant polyclonal antibody and methods of manufacture |
| 01/26/2006 | CA2574060A1 Immune modulating compounds from fungi |
| 01/26/2006 | CA2573821A1 Combination treatment for non-hematologic malignancies using an anti-igf-1r antibody |
| 01/26/2006 | CA2572825A1 Compositions for multi-step delivery of hot-spots radiation to cancer cells |
| 01/26/2006 | CA2571452A1 Identifying virally infected and vaccinated organisms |
| 01/26/2006 | CA2570998A1 Improved efficacy of active immunotherapy by integrating diagnostic with therapeutic methods |
| 01/26/2006 | CA2568952A1 Novel antigen-binding polypeptides and their uses |
| 01/26/2006 | CA2568534A1 Vegf inhibitors for the treatment of malignant pleural effusion |
| 01/25/2006 | EP1619250A1 WSX receptor and ligands |
| 01/25/2006 | EP1619207A2 HLA-A2.1 binding peptides derived from HCV and their uses |
| 01/25/2006 | EP1618890A1 Use of antibodies in a very low dose for the vaccination against cancer |
| 01/25/2006 | EP1618889A2 Influenza Vaccine |